logo
Why OptiNose Inc. (OPTN) Surged On Thursday?

Why OptiNose Inc. (OPTN) Surged On Thursday?

Yahoo22-03-2025

We recently published a list of . In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) stands against other micro-, small-cap firms that dominate Thursday's gains.
The stock market edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve's decision to keep rates unchanged.
The tech-heavy Nasdaq decreased by 0.33 percent, the S&P 500 declined by 0.22 percent, and the Dow Jones dipped by 0.03 percent.
On Thursday, investors immediately booked profits following the lack of fresh catalysts to further boost buying appetite.
However, 10 companies under the micro- to small-cap sectors noticeably defied market pessimism, having surged by double to triple digits. In this article, we have identified Thursday's 10 best performers and detailed the reasons behind their gains.
We classify micro-cap companies as those between $50 million and $300 million in market capitalization, while small-cap firms are those with $300 million and $2 billion in market capitalization.
A white-coat wearing pharmacist holding a bottle of a specialized therapeutic product.
OptiNose grew its share prices by 52.50 percent on Thursday to finish at $9.15 apiece as investors took heart from news that it is set to be acquired by Paratek Pharmaceuticals for $330 million.
In a statement on Thursday, Paratek announced that it entered into a definitive merger agreement with OPTN, under which, Paratek will acquire OPTN, including its approved product XHANCE (fluticasone propionate).
After the transaction, OPTN shareholders will expect to receive $14 for each share, including the payment of contingent value rights (CVRs) tied to future commercial milestones.
According to Paratek, the acquisition plan would boost its commercial portfolio beyond the flagship antibiotic NUZYRA.
'We have long recognized the potential of XHANCE to transform how CRS is treated. We have been exploring opportunities to make more patients and doctors aware of XHANCE and the benefits it can offer to patients suffering from this common condition. Paratek, with its robust commercial and medical capabilities, has the potential to rapidly extend awareness of XHANCE to primary care providers who treat the majority of patients with CRS,' said OPTN CEO Ramy Mahmoud.
Overall, OPTN ranks 4th on our list of micro-, small-cap firms that dominate Thursday's gains. While we acknowledge the potential of OPTN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as OPTN but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Adobe Stock Slumps as Results Leave Some Waiting for More Signs of AI Success
Adobe Stock Slumps as Results Leave Some Waiting for More Signs of AI Success

Yahoo

time18 minutes ago

  • Yahoo

Adobe Stock Slumps as Results Leave Some Waiting for More Signs of AI Success

Adobe shares slumped Friday, as the design software developer failed to impress with its quarterly results, despite topping Wall Street estimates. Several Wall Street analysts indicated Adobe's results didn't suggest enough progress with its own AI offerings to ease worries it could be held back by growing competition and AI disruption. Deutsche Bank said it expects the stock 'to remain range-bound until the company demonstrates more tangible success from AI."Adobe (ADBE) shares slumped Friday, as the design software developer failed to impress with its quarterly results, despite topping Wall Street estimates and boosting its full-year outlook. The stock led S&P 500 decliners by sinking nearly 6% in recent trading to roughly $390, leaving shares down 12% for 2025. "The key investor question remains when (if) AI innovation can move the needle," wrote Morgan Stanley analysts, who added the quarter "brought little to quell the bear concern around AI contribution being unable to reaccelerate growth while bulls must remain patient for encouraging AI metrics to move the needle." Still, the analysts said they are "overweight" on the stock with a $510 target, expecting Adobe AI monetization to ramp up in the next fiscal year. Jefferies analysts, who reiterated a "buy" rating and $590 price target on Adobe's potential growth driven by its AI offerings, echoed the comments, writing that while the firm's earnings showed some AI progress, it was "maybe not enough to appease bears." Jefferies also noted that Adobe's forecast, while higher, would imply a slowdown in growth in the fiscal fourth quarter, though they added they believe it "reflects management's conservatism amid ongoing macro uncertainties." Bank of America, which raised its target to $475 from $424 on Adobe's outlook and AI growth potential, said the company demonstrated "solid execution in a weaker software backdrop," calling it a "break from this reporting season, with most software companies opting not to flow through upside to the full year." Citi analysts, however, were less convinced, citing worries growing competition and AI disruption could hold Adobe back. Citi issued a "neutral" rating for the stock and $465 target. Deutsche Bank analysts, who affirmed their "hold" rating and $475 target, said they "expect the stock to remain range-bound until the company demonstrates more tangible success from AI." Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Baird Upgrades Urban Outfitters, Inc. (URBN) on Nuuly Growth
Baird Upgrades Urban Outfitters, Inc. (URBN) on Nuuly Growth

Yahoo

time18 minutes ago

  • Yahoo

Baird Upgrades Urban Outfitters, Inc. (URBN) on Nuuly Growth

Urban Outfitters, Inc. (NASDAQ:URBN) is among the 10 Best Growth Stocks Under $100 to Buy Now. Mark Altschwager, an analyst at Baird, raised the price target for Urban Outfitters, Inc. (NASDAQ:URBN) to $90 from $75, while elevating the rating from 'Neutral' to 'Outperform'. This price appreciation of 20% underscores the company's position for a turnaround. The company recently reported strong first-quarter results, with a 74% increase in net income stemming from margin improvement. The investors are closely monitoring the giant's subscription/rental business, Nuuly, which is anticipated to grow 43% to $540m this year. A frontline retail worker organizing apparel products in a store. To sum it up, Urban Outfitters, Inc. (NASDAQ:URBN) is a unique 'growth at a reasonable price' stock that is witnessing strong comp sales growth in each of its brands, and with even more room to grow via both price hikes and traffic increases. As long as the company is able to capitalize on Nuuly, we can expect it to show sustained momentum. Urban Outfitters, Inc. (NASDAQ:URBN) is a Pennsylvania-based fashion business that operates through three segments: Retail, Wholesale, and Subscription. Incepted in 1970, the company serves its customers directly through websites and retail stores, as well as social media and external sources. While the broader market delivered nearly 100% return in five years, URBN has exhibited a return of 295%. While we acknowledge the potential of URBN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.
Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.

Yahoo

time18 minutes ago

  • Yahoo

Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.

ETF launches continue to surge, with some popular market voices putting their names on funds. Starting an ETF involves significant expenses, including SEC filing and listing fees. Funds need strong performance and substantial assets under management to remain viable. A string of widely followed strategists, economists, and investors have launched exchange-traded funds in recent years. There's famed NYU professor Nouriel Roubini — known colloquially as "Dr. Doom" — and his Atlas America Fund (USAF). Then there's Dan Ives — the tech and AI permabull who can often be found on CNBC wearing fluorescent blazers — who has parlayed his bold analyst calls into the Wedbush AI Revolution ETF (IVES). And let's not forget Fundstrat's Tom Lee — former chief equity strategist at JPMorgan — and his Granny Shots US Large Cap ETF (GRNY). They've stepped into a crowded market with thousands of funds competing for investors' money. A record 723 ETFs came to market in 2024 alone. And they're using their own high-profile personal brands to stand out in a crowded marketplace. But starting a fund is an entirely different beast than keeping one afloat for any sustained amount of time. Yes, strong performance is crucial. But running a fund is expensive, and it takes much more than good returns to ensure success. To start, the cost to launch a fund is hefty. Firms are looking at a $50,000-to-$100,000 filing fee with the SEC, according to Zachary Evans, analyst for passive strategies at Morningstar. puts that number between $100,000 and $500,000. Depending on the type of fund, there also may be an initial listing fee with NYSE or Nasdaq. But the bills don't stop there. Listing fees with the exchange come due every year. With Nasdaq, for example, it's a $4,000 annual fee. Then there's a long list of costs associated with running the fund itself, Evans said. Paying the staff who execute the trades. Paying compliance and a risk-management team. Paying sales and advertising teams to market the fund. Paying rent for your office space. And so on. It all adds up, and it means funds need to amass significant assets under management. ETF providers make money through the annual fees, or expense ratios, they charge investors. So the more money they manage, the more money they're bringing in. Performance also plays a role here — if a fund's value rises by 20% in a year, the fees it extracts will be 20% higher. "This can vary quite a bit, but a baseline number we've heard is that it should cost around $200,000 a year to run an ETF," Evans told BI. "More complicated strategies will cost more, simpler strategies will cost less, or if it's from a large firm that has economies of scale, it might cost less as well." He added: "Say an ETF charges 50 basis points with annual expenses of $200,000 a year. You need $40 million AUM in order to break even on that product." For some funds, there's also pressure associated with seed money. When an ETF launches, Evans said it might have some investors who promise to keep their capital locked up in the fund for a set period of time — say two or three years. Once that period ends, if the investors pull their money, it can be an existential threat to a fund if they haven't pulled in enough money from elsewhere. "Once that seed money dries up, in order for them to endure, they need to make sure they have enough investor interest, enough assets to sustain them," Evans said. Fund closures are increasingly common. Evans said a little more than 200 closed in 2023 — a record — and just under 200 closed in 2024. "As more companies are launching their products, more companies are closing down their products — the vast majority of which have really failed to catch on with investors," Evans said. "They've failed to generate either the performance or, in effect, the asset level to support these products." Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store